ABSTRACT
Objective:To study the early effects of intact-umbilical cord milking (I-UCM) and cut-umbilical cord milking (C-UCM) for the prevention of anemia of prematurity in preterm infants.Method:From January 2019 to October 2019, C-section delivered infants with gestational age <34 weeks were randomly assigned into I-UCM group and C-UCM group. Hematological parameters at different timepoints after birth, iron status, incidence of anemia within 7 d after birth, blood transfusions, transcutaneous bilirubin levels and the total duration of phototherapy were collected and analyzed.Result:A total of 60 cases were enrolled, including 30 in I-UCM group and 30 in C-UCM group. I-UCM group had significant higher levels of hemoglobin (Hb), hematocrit (Hct) and serum iron on admission ( P<0.05). Comparing with C-UCM group, Hb and Hct were significantly higher in I-UCM group at 7 d and 14 d after birth ( P<0.05). Lower prevalence of anemia within 1 week [3.3% (1/30) vs. 33.3% (10/30), P<0.05] and less blood transfusions during hospitalization [13.3% (4/30) vs. 56.7% (17/30)] were noted in I-UCM group. No statistically significant differences existed between the two groups in phototherapy duration and the peak bilirubin levels ( P>0.05). Conclusion:I-UCM can provide more placental transfusion at birth to increase Hb levels and iron storage to prevent and reduce anemia in preterm infants.
ABSTRACT
Anemia of prematurity is one of the most common and serious problems affecting quality of life and survival of premature infants.Recent studies have found that delayed cord clamping or umbilical cord milking may prevent and control anemia of prematurity by providing a placental transfusion and elevating hemoglobin concentration.This review is a summary of current evidence on the effects of different umbilical cord handling on premature infants with anemia,with potential benefits and adverse effects discussed.
ABSTRACT
OBJECTIVE:To explore the clinical efficacy and safety of cetuximab combined with NP regimen and radiotherapy in the treatment of advanced non-small cell lung cancer(NSCLC). METHODS:76 cases of advanced NSCLC were selected and randomly divided into control group and observation group according to different therapy methods,with 38 cases in each group. Control group received NP regimen(cisplatin 25 mg/m2+navelbine 12.5 mg/m2)+thoracic IMRT;observation group was additional-ly given cetuximab 400 mg/m2(first day),with maintenance dose of 250 mg/m2 weekly and last for 13 weeks. Short-term efficacy, survival situation were compared between 2 groups as well as the levels of T lymphocyte,Th1,Th2,immuneglobulin(Ig) and complement. The occurrence of ADR was recorded. RESULTS:The total effective rate of observation group was 86.84%,which was significantly higher than that of control group(65.79%),with statistical significance(P0.05). There was no statistical significance in the incidence of ADR between 2 groups (P>0.05). CONCLUSIONS:Cetuximab combined with NP regimen and radiotherapy can improve clinical efficacy of advanced NSCLC,improve survival quality,prolong survival time and promote the recovery of Ig,complement and T lymphocyte,with good safety.